Ipsen has patented a storage-stable liposomal formulation of irinotecan, designed to minimize the formation of lyso-phosphatidylcholine during storage. The composition includes cholesterol, phospholipids, and irinotecan sucrose octasulfate, with specific ratios and pH conditions to enhance stability over six months at controlled temperatures. GlobalData’s report on Ipsen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ipsen, Cancer treatment biomarkers was a key innovation area identified from patents. Ipsen's grant share as of July 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
Stabilized irinotecan liposomes with reduced lyso-pc formation
The granted patent US12059497B2 describes a storage-stabilized liposomal composition of irinotecan, which is a chemotherapeutic agent, encapsulated in unilamellar liposomes. The composition includes cholesterol, one or more phospholipids, and irinotecan sucrose octasulfate (SOS). Key parameters of the formulation include a specific irinotecan to total phospholipids weight ratio of approximately 500 grams per mole, a gram-equivalent ratio of co-encapsulated irinotecan and sucrose octasulfate ranging from 0.85 to 1.2, and a pH of 7.25 to 7.5 prior to storage. Notably, the composition demonstrates stability, maintaining less than 20 mol% lyso-phosphatidylcholine (lyso-PC) relative to total phospholipids after six months of storage at 2-8°C.
Further claims detail the specific phospholipids used, including phosphatidylcholine and PEG-phosphatidylethanolamine, with particular emphasis on 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and its concentration ratios with cholesterol. The patent also outlines the stability of the composition over extended periods, indicating that after six, nine, twelve, and twenty-four months of storage, the lyso-PC content remains below specified thresholds, quantified using HPLC methods. Additional components such as triethylammonium or diethylammonium ions and buffering agents are also included in the formulation, contributing to the overall stability and efficacy of the liposomal composition. This patent presents a comprehensive approach to enhancing the storage stability of irinotecan, potentially improving its therapeutic application in cancer treatment.
To know more about GlobalData’s detailed insights on Ipsen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
